|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.3 CHF | +0.12% |
|
-1.10% | +14.16% |
| Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
| Apr. 04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
Basilea Pharmaceutica Ltd. announced that it will accelerate the repayment of its senior secured loan. The senior secured loan from Athyrium Capital Management, LP had an initial total amount of CHF 75 million and a two-year term from September 2022 to September 2024. The repayment started as of First Quarter 2023 on a quarterly basis.
Basilea now plans to have the loan fully repaid by the end of First Quarter 2024.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.16% | 529M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
BASILEA PHARMACEUTICA AG 
